Genomics announces next stage of global roll-out of its predictive clinical tool Health Insights - the first ever UKCA-marked and MHRA registered test that combines genetic and clinical factors to predict and prevent common diseases

• Health Insights UK is Genomics' predictive clinical tool. It provides genetic risk testing as a secure, end-to-end solution based on a saliva sample that can be collected at home. The test provides doctors with their patient's integrated risk scores, which combine the genetic component of risk and relevant clinical risk factors, enabling healthcare professionals to make better informed decisions and to give tailored advice to their patients.
  
  
• Health Insights is now available nationwide across Great Britain, with new locations being on-boarded weekly. Providers of the test include Bupa, Spire Healthcare, and Well Life Clinics. The current UK test covers cardiovascular disease, type 2 diabetes, breast cancer, and prostate cancer.
  
  
• Genomics has been recognised in the 2025 Sunday Times 100 Tech as one of Britain's fastest-growing private tech companies.

OXFORD, England, June 17, 2025 /PRNewswire/ -- Genomics, a healthcare company using large-scale genetic information to develop innovative precision healthcare tools and to accelerate drug discovery, has announced the launch of its Health Insights test across Great Britain, the first UKCA marked and MHRA registered product that combines genetic and clinical factors to predict and prevent common diseases. The announcement was made live on stage at HLTH Europe 2025, in Amsterdam.

The company's Health Insights UK test provides risk prediction tools for the major preventable diseases. The test provides healthcare professionals with a new generation of powerful, personalised, risk information about their patients, and ushers in a new area of preventative medicine. With the Health Insights report, physicians can get the right people into the right prevention and screening programmes at the right time, and provide personalised recommendations to their patients. This will empower individuals to become co-pilots on their health journey, rather than just passengers.

The test is based on polygenic risk scores (PRS), which use sophisticated algorithms to combine information from millions of places in our DNA to give an overall summary of a person's genetic susceptibility to a particular disease. These scores are largely uncorrelated with family history of disease and with clinical risk factors, which means that most people, and their doctors, will have no idea which diseases they are at higher risk of because of their genetics.